Effectiveness and safety of first-line empirical Helicobacter pylori eradication regimens in Switzerland: an interim analysis from a prospective multicentre registry (Hp-EuReg).

IF 1.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Michael Doulberis, Daniele Riva, Ioannis Linas, Patrick Mosler, Tom Völler, Imen Jallouli, Jürg Knuchel, Claudia Gregoriano, Pablo Gressot, Thrasyvoulos Gkretzios, Christos Kiosses, Thomas Balanis, Radu Tutuian, Hasan Kulaksiz, Anna Cano-Català, Pablo Parra, Leticia Moreira, Olga P Nyssen, Francis Megraud, Colm O' Morain, Thomas Kuntzen, Javier P Gisbert
{"title":"Effectiveness and safety of first-line empirical Helicobacter pylori eradication regimens in Switzerland: an interim analysis from a prospective multicentre registry (Hp-EuReg).","authors":"Michael Doulberis, Daniele Riva, Ioannis Linas, Patrick Mosler, Tom Völler, Imen Jallouli, Jürg Knuchel, Claudia Gregoriano, Pablo Gressot, Thrasyvoulos Gkretzios, Christos Kiosses, Thomas Balanis, Radu Tutuian, Hasan Kulaksiz, Anna Cano-Català, Pablo Parra, Leticia Moreira, Olga P Nyssen, Francis Megraud, Colm O' Morain, Thomas Kuntzen, Javier P Gisbert","doi":"10.57187/s.4191","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> Helicobacter pylori infection remains prevalent globally. Despite the relatively low reported prevalence in Switzerland, the actual burden is thought to be higher, primarily due to migration. To date, limited evidence is available regarding the effectiveness of Helicobacter pylori eradication therapy in Switzerland.</p><p><strong>Methods: </strong>This is a sub-study of the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, multicentre, prospective, non-interventional registry of the routine clinical practice of gastroenterologists. All adult patients with Helicobacter pylori infections were systematically registered in the AEG-REDCap electronic case report form from 2013 to December 2023. Swiss data were analysed for effectiveness on a modified intention-to-treat (mITT) basis, assessing both the therapy duration and the acid inhibition administered with treatment.</p><p><strong>Results: </strong>A total of 486 adult patients diagnosed with Helicobacter pylori infection were evaluated. Of these, 428 (88%) were treatment-naïve patients. A total of 283 patients with available follow-up were evaluated for effectiveness, adverse events, and compliance. Two first-line regimens accounted for over 90% of cases: amoxicillin-clarithromycin triple therapy in 49% and 10-day single-capsule bismuth quadruple therapy (containing metronidazole-tetracycline-bismuth) in 42%. The overall modified intention-to-treat effectiveness was 92%, achieving 91% in the low-dose proton pump inhibitor (PPI) group (20 mg omeprazole equivalent twice daily) and 96% in the group receiving high-dose (80 mg omeprazole equivalent twice daily) proton pump inhibitors. The lowest effectiveness (82%, 28/34 cases) was reported with 7-day amoxicillin-clarithromycin triple therapy, while the highest effectiveness (97%, 100/103 cases) was achieved with single-capsule bismuth quadruple therapy. Regarding safety, the overall incidence of at least one adverse event was 8.5%, and no serious adverse events were reported.</p><p><strong>Conclusions: </strong>In Switzerland, 10-day single-capsule bismuth quadruple therapy with metronidazole, tetracycline, and bismuth demonstrated high eradication success (>90%) and represents a promising empirical first-line treatment option in routine clinical practice.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"155 ","pages":"4191"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.4191","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background:  Helicobacter pylori infection remains prevalent globally. Despite the relatively low reported prevalence in Switzerland, the actual burden is thought to be higher, primarily due to migration. To date, limited evidence is available regarding the effectiveness of Helicobacter pylori eradication therapy in Switzerland.

Methods: This is a sub-study of the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, multicentre, prospective, non-interventional registry of the routine clinical practice of gastroenterologists. All adult patients with Helicobacter pylori infections were systematically registered in the AEG-REDCap electronic case report form from 2013 to December 2023. Swiss data were analysed for effectiveness on a modified intention-to-treat (mITT) basis, assessing both the therapy duration and the acid inhibition administered with treatment.

Results: A total of 486 adult patients diagnosed with Helicobacter pylori infection were evaluated. Of these, 428 (88%) were treatment-naïve patients. A total of 283 patients with available follow-up were evaluated for effectiveness, adverse events, and compliance. Two first-line regimens accounted for over 90% of cases: amoxicillin-clarithromycin triple therapy in 49% and 10-day single-capsule bismuth quadruple therapy (containing metronidazole-tetracycline-bismuth) in 42%. The overall modified intention-to-treat effectiveness was 92%, achieving 91% in the low-dose proton pump inhibitor (PPI) group (20 mg omeprazole equivalent twice daily) and 96% in the group receiving high-dose (80 mg omeprazole equivalent twice daily) proton pump inhibitors. The lowest effectiveness (82%, 28/34 cases) was reported with 7-day amoxicillin-clarithromycin triple therapy, while the highest effectiveness (97%, 100/103 cases) was achieved with single-capsule bismuth quadruple therapy. Regarding safety, the overall incidence of at least one adverse event was 8.5%, and no serious adverse events were reported.

Conclusions: In Switzerland, 10-day single-capsule bismuth quadruple therapy with metronidazole, tetracycline, and bismuth demonstrated high eradication success (>90%) and represents a promising empirical first-line treatment option in routine clinical practice.

瑞士一线经验幽门螺杆菌根除方案的有效性和安全性:来自前瞻性多中心注册(Hp-EuReg)的中期分析。
背景:幽门螺杆菌感染仍在全球流行。尽管瑞士报告的患病率相对较低,但实际负担被认为更高,主要是由于移民。迄今为止,关于瑞士幽门螺杆菌根除疗法的有效性的证据有限。方法:这是欧洲幽门螺杆菌管理登记(Hp-EuReg)的一项子研究,Hp-EuReg是一项国际、多中心、前瞻性、非介入性的胃肠病学家常规临床实践登记。2013年至2023年12月,所有幽门螺杆菌感染的成年患者系统地登记在AEG-REDCap电子病例报告表格中。在修改意向治疗(mITT)的基础上分析瑞士数据的有效性,评估治疗持续时间和治疗时的酸抑制作用。结果:共对486例诊断为幽门螺杆菌感染的成人患者进行了评估。其中428例(88%)为treatment-naïve患者。共有283名患者接受了随访,评估其有效性、不良事件和依从性。两种一线方案占90%以上的病例:阿莫西林-克拉霉素三联治疗占49%,10天单胶囊铋四联治疗(含甲硝唑-四环素-铋)占42%。总体改良意向治疗有效性为92%,低剂量质子泵抑制剂(PPI)组(20mg奥美拉唑当量每日两次)达到91%,高剂量质子泵抑制剂(80mg奥美拉唑当量每日两次)组达到96%。7天阿莫西林-克拉霉素三联治疗的疗效最低(82%,28/34例),而单胶囊铋四联治疗的疗效最高(97%,100/103例)。在安全性方面,至少一项不良事件的总发生率为8.5%,未报告严重不良事件。结论:在瑞士,10天的甲硝唑、四环素和铋联合单胶囊四联治疗显示出很高的根除成功率(>90%),在常规临床实践中是一种很有前景的经验一线治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Swiss medical weekly
Swiss medical weekly 医学-医学:内科
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
3-8 weeks
期刊介绍: The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信